Global Active Pharmaceutical Ingredients Market Overview:
According to SPER Market Research, the global active pharmaceutical ingredients market estimated to reach USD 262.40 Bn by 2030 with a CAGR of 6.8%. Market growth is driven mainly by factors like rising drug R&D, the increasing incidence of chronic diseases, the growing importance of generics, and the increasing uptake of biopharmaceuticals. The growth of this market is going to be controlled by the unfavourable drug price control policies and high manufacturing costs.
COVID-19 Impact on the Active Pharmaceutical Ingredient (API) Market
With the WHO declaring the COVID-19 outbreak a pandemic, a mix of established pharmaceutical and biopharmaceutical companies, as well as small start-ups, have stepped forward to develop treatments that target the infection. The economic and social burden of pandemics has prompted government bodies to increase funding for vaccine development on a global scale. Increase in funding and research for development of pharmaceutical products will drive growth for the market. However, corona virus outbreak has disrupted business and economic activities globally in the first quarter of 2020. It is expected to have a short-term impact on the active pharmaceutical ingredients market to a certain extent.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2019-2030 |
| Base year considered | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | By type, By Manufacturer, By types of Synthesis, By types of Drug, By types of Therapeutic action, By Region |
| Geographies covered | North America, Europe, Asia, and Rest of the World |
| Companies Covered | Pfizer, Inc. (US), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), AstraZeneca (UK), Cipla, Inc. (India), Mylan N.V. (US), Dr. Reddy’s Laboratories Ltd. (India), Sun Pharmaceutical Industries Ltd. (India), API Pharma Tech (India), BDR Pharmaceuticals Internationals Pvt. Ltd. (India), Sreepathi Pharmaceuticals Limited (India), Shilpa Medicare Limited (India) |
Driver: Increasing incidence of chronic diseases
The incidence of chronic diseases such as diabetes, coronary artery disease, chronic obstructive pulmonary disease (COPD), asthma, hepatitis, arthritis, and cancer has increased globally. This can be attributed to the rising geriatric population across the globe. Changing lifestyles, and dietary changes as a result of rapid urbanization. According to the International Diabetes Federation, in 2019, 463 million people worldwide were diagnosed with diabetes. Moreover, the number of new cancer cases per year is expected to rise to 23.6 million by 2030.
Challenges: High manufacturing costs
The high manufacturing cost of APIs (chemical synthesis of APIs also often requires expensive and uncommon building blocks and raw materials), the costs of obtaining regulatory approvals are relatively higher for firms with small volumes these are major challenges for growth of this market in low- and medium-income countries with poor reimbursement scenarios.
Opportunity: Emerging biosimilars market
The rising incidence of various diseases, the increasing number of off-patent biologic drugs, positive outcomes in ongoing clinical trials for biosimilars, and the rising demand for biosimilars in different therapeutic applications (such as rheumatoid arthritis and blood disorders) are the major factors driving the growth of the biosimilars market. The expiration of patents and other intellectual property rights for originator biologics over the next decade is expected to open up opportunities for biosimilars to enter the market.
Active Pharmaceutical Ingredient (API) Market Segmentation:
By Type: Based on the type, APIs market is segmented as; Innovative APIs, Generic APIs.
By Type of Manufacturer: Based on the type of Manufacturer, APIs market is segmented as; Captive Manufacturers, Merchant Manufacturers (Merchant Manufacturers Market, by Type, Innovative Merchant API Manufacturers, Generic Merchant API Manufacturers, Merchant Manufacturers Market by Type of Synthesis, Synthetic APIs, Biotech APIs).
By Type of Synthesis: Based on the type of Synthesis, APIs market is segmented as; Synthetic APIs Market (Synthetic APIs Market, by Type, Innovative Synthetic APIs, Generic Synthetic APIs), Biotech APIs Market (Biotech APIs Market, by Type, Innovative Biotech APIs, Biosimilars, Biotech APIs Market, by Product, Monoclonal Antibodies, Hormones, Cytokines, Fusion, Proteins, Therapeutic Enzymes, Vaccines, Blood Factors, Biotech APIs Market, by, Expression System, Mammalian Expression Systems, Microbial Expression Systems, Yeast Expression Systems, Insect Expression Systems, Plant expression systems).
By Type of Drug: Based on the type of Drugs, APIs market is segmented as; Prescription Drugs, Over-the-counter Drugs.
By Therapeutic Application: Based on the type of Therapeutic Application, APIs market is segmented as; Communicable Diseases, Oncology, Diabetes, Cardiovascular Disease, Pain management, Respiratory Diseases, Other Therapeutic Applications (Orthopedics, Urology and Nephrology, Ophthalmology, Pulmonology, Women’s Health, and Gastroenterology).
By Region: North America owns the largest share of this market due to prevalence of the growing incidence of preventable chronic diseases, increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. COVID-19 Impact on the Active Pharmaceutical Ingredient (API) Market
4.4. Market Trends
5. Active Pharmaceutical Ingredient (API) Market, By Type, 2019-2030 (USD Million)
5.1. Innovative APIs
5.2. Generic APIS
6. APIs Market, by Type of Manufacturer, 2019-2030 (USD Million)
6.1. Captive Manufacturers
7. Merchant Manufacturers
7.1.1. Merchant Manufacturers Market, by Type
7.1.2. Innovative Merchant API Manufacturers
7.1.3. Generic Merchant API Manufacturers
7.1.4. Merchant Manufacturers Market, by Type of Synthesis
7.1.5. Synthetic APIs
7.1.6. Biotech APIs
8. APIs market, by Type of Synthesis, 2019-2030 (USD Million)
8.1. Synthetic APIs Market
8.1.1. Synthetic APIs Market, by Type
8.1.2. Innovative Synthetic APIs
8.1.3. Generic Synthetic APIs
8.2. Biotech APIs Market
8.2.1. Biotech APIs Market, by Type
8.2.2. Innovative Biotech APIs
8.2.3. Biosimilars
8.2.4. Biotech APIs Market, by Product
8.2.5. Monoclonal Antibodies
8.2.6. Hormones
8.2.7. Cytokines
8.2.8. Fusion Proteins
8.2.9. Therapeutic Enzymes
8.2.10. Vaccines
8.2.11. Blood Factors
8.2.12. Biotech APIs Market, by Expression System
8.2.13. Mammalian Expression Systems
8.2.14. Microbial Expression Systems
8.2.15. Yeast Expression Systems
8.2.16. Insect Expression Systems
8.2.17. Other Expression Systems (Plant expression systems)
9. APIs Market, by Type of Drug, 2019-2030 (USD Million)
9.1. Prescription Drugs
9.2. Over-the-counter Drugs
10. APIs Market, by Therapeutic Application, 2019-2030 (USD Million)
10.1. Communicable Diseases
10.2. Oncology
10.3. Diabetes
10.4. Cardiovascular Disease
10.5. Pain management
10.6. Respiratory Diseases
10.7. Other Therapeutic Applications (Orthopedics, Urology and Nephrology, Ophthalmology, Pulmonology, Women’s Health, and Gastroenterology)
11. API Market, by Region, 2019-2030 (USD Million)
11.1. North America
11.1.1. US
11.1.2. Canada
11.2. Europe
11.2.1. Germany
11.2.2. France
11.2.3. UK
11.2.4. Italy
11.2.5. Spain
11.2.6. Hungary
11.2.7. Rest of Europe
11.3. Asia
11.3.1. Japan
11.3.2. China
11.3.3. India
11.3.4. South Korea
11.3.5. Rest of Asia
11.4. Rest of the World
11.5. Israel
11.6. Other countries
12. Competitive Landscape
12.1. Introduction
12.2. Market Share Analysis, By Key Players
12.3. Competitive Scenario
12.3.1. Product Launches
12.3.2. Partnerships, Collaborations and Agreements
12.3.3. Acquisitions
12.3.4. Expansions
12.3.5. Other Developments
13. Company Profiles
13.1. AbbVie Inc. (US)
13.2. API Pharma Tech (India)
13.3. AstraZeneca (UK)
13.4. BDR Pharmaceuticals Internationals Pvt. Ltd. (India)
13.5. Boehringer Ingelheim (Germany)
13.6. Bristol-Myers Squibb (US)
13.7. Cipla, Inc. (India)
13.8. Dr. Reddy’s Laboratories Ltd. (India)
13.9. Eli Lilly and Company (US)
13.10. F. Hoffmann-La Roche Ltd. (Switzerland)
13.11. GlaxoSmithKline plc (UK)
13.12. Merck & Co., Inc. (US)
13.13. Mylan N.V. (US)
13.14. Novartis International AG (Switzerland)
13.15. Pfizer, Inc. (US)
13.16. Sanofi (France)
13.17. Shilpa Medicare Limited (India)
13.18. Sreepathi Pharmaceuticals Limited (India)
13.19. Sun Pharmaceutical Industries Ltd. (India)
13.20. Teva Pharmaceutical Industries Ltd. (Israel)
14. Appendix